First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer

Video

Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.

Results of the phase II IMvigor210 clinical trial found that atezolizumab, a PD-L1 inhibitor, produced an overall response rate of 24% in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma. The study (abstract LBA4500) reported a median overall survival rate of 14.8 months, regardless of PD-L1 expression.

The data were presented by Arjun V. Balar, MD, of the NYU Perlmutter Cancer Center in New York, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. In this video Dr. Balar discusses the results.

Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content